Although early preclinical data suggested that inhibition of the histone acetyltransferases KAT6A and 6B induces senescence and arrests tumor growth in cell lines and animal models7,13, it is difficult to predict the translatability in the clinical setting, given the complexity and heterogeneity of human cancer. Here, KAT6A is linked to neoplasm.